These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35815178)

  • 1. New-Onset Psychotic Symptoms Following Abrupt Buprenorphine/Naloxone Discontinuation in a Female Patient with Bipolar Disorder: A Case Report.
    Lin Y; Zhang AD; Sun CF; White JB; Qi A; Farrell JA; Trestman RL; Martin RK; Kablinger AS
    Psychopharmacol Bull; 2022 Jun; 52(3):72-80. PubMed ID: 35815178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Course and treatment of buprenorphine/naloxone withdrawal: an analysis of case reports.
    Westermeyer J; McCance-Katz EF
    Am J Addict; 2012; 21(5):401-3. PubMed ID: 22882389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sublingual buprenorphine-naloxone precipitated withdrawal-A case report with review of literature and clinical considerations.
    Bhatia G; Sarkar S
    Asian J Psychiatr; 2020 Oct; 53():102121. PubMed ID: 32460142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case Report: Buprenorphine Induction Using Transdermal Buprenorphine in a Veteran With Opioid Use Disorder and Psychosis, Managing Precipitated Withdrawal.
    Kinasz KR; Herbst ED; Kalapatapu RK
    Mil Med; 2020 Sep; 185(9-10):e1872-e1875. PubMed ID: 32314788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of buprenorphine-precipitated withdrawal managed with high-dose buprenorphine.
    Quattlebaum THN; Kiyokawa M; Murata KA
    Fam Pract; 2022 Mar; 39(2):292-294. PubMed ID: 34173647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine/naloxone (Suboxone®) withdrawal may facilitate antipsychotic-induced priapism. A case report.
    Jannini TB; Di Lorenzo G; Mariano A; Santini R; Ciocca G; Jannini EA; Siracusano A; Niolu C
    Riv Psichiatr; 2022; 57(5):246-250. PubMed ID: 36200467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.
    Amass L; Ling W; Freese TE; Reiber C; Annon JJ; Cohen AJ; McCarty D; Reid MS; Brown LS; Clark C; Ziedonis DM; Krejci J; Stine S; Winhusen T; Brigham G; Babcock D; Muir JA; Buchan BJ; Horton T
    Am J Addict; 2004; 13 Suppl 1(Suppl 1):S42-66. PubMed ID: 15204675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report.
    Coish R; Hardial J
    J Addict Med; 2023 Jan-Feb 01; 17(1):114-116. PubMed ID: 35916416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of buprenorphine + naloxone sublingual tablet in the treatment of neonatal opioid withdrawal syndrome: Two case reports.
    Ulu E; Kandeğer A; Meriç R
    J Addict Dis; 2022; 40(3):432-438. PubMed ID: 34775907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone.
    Antoine D; Huhn AS; Strain EC; Turner G; Jardot J; Hammond AS; Dunn KE
    Am J Addict; 2021 Jan; 30(1):83-87. PubMed ID: 32572978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid Micro-induction of Buprenorphine/Naloxone for Opioid Use Disorder in a Critically ill Intubated Patient: A Case Report.
    Hamata B; Griesdale D; Hann J; Rezazadeh-Azar P
    J Addict Med; 2020 Dec; 14(6):514-517. PubMed ID: 32649330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double blind randomized clinical trial of buprenorphine augmentation for treatment of psychotic symptoms in opioid addicted bipolar patients.
    Khalili N; Sabahi A; Vahedian M; Alimardanzadeh M
    J Opioid Manag; 2019; 15(5):362-366. PubMed ID: 31849027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 48-hour Induction of Transdermal Buprenorphine to Sublingual Buprenorphine/Naloxone: The IPPAS Method.
    Azar P; Wong JSH; Mathew N; Vogel M; Perrone J; Herring AA; Krausz RM; Montaner JSG; Greenwald MK; Maharaj AR
    J Addict Med; 2023 Mar-Apr 01; 17(2):233-236. PubMed ID: 36149002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose buprenorphine for treatment of high potency opioid use disorder.
    Danilewitz M; McLean M
    Drug Alcohol Rev; 2020 Feb; 39(2):135-137. PubMed ID: 31769109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elective Naloxone-Induced Opioid Withdrawal for Rapid Initiation of Medication-Assisted Treatment of Opioid Use Disorder.
    Phillips RH; Salzman M; Haroz R; Rafeq R; Mazzarelli AJ; Pelletier-Bui A
    Ann Emerg Med; 2019 Sep; 74(3):430-432. PubMed ID: 30773411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
    Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
    J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse.
    Moncrieff J
    Acta Psychiatr Scand; 2006 Jul; 114(1):3-13. PubMed ID: 16774655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series.
    Klaire S; Zivanovic R; Barbic SP; Sandhu R; Mathew N; Azar P
    Am J Addict; 2019 Jul; 28(4):262-265. PubMed ID: 30901127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Transition to Buprenorphine in a Patient With Methadone-Related QTc Interval Prolongation.
    Brogdon H; Facer KL; Cox EJ; Carlson RH; Wurzel JF
    J Addict Med; 2022 Jul-Aug 01; 16(4):488-491. PubMed ID: 34864786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.